Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip
25 April 2024 - 2:30PM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced that it
has entered into a service agreement with NoiseFigure Research,
Inc. (NFR), a premier application specific integrated circuits
(ASICs) service provider.
As part of the agreement, Autonomix will work
with NFR to assess its ASIC microchip and upgrade the chip to its
second-generation in preparation for human clinical testing in the
Company’s planned pivotal trial in 2025. Additionally, NFR will
evaluate a subsequent version meant to enable commercial production
volumes.
Lori Bisson, Chief Executive Officer of
Autonomix said, “This collaboration with NFR is an important step
in the evolution of our technology and simple approach to a
procedure for pain management and other indications. The
proprietary ASIC is the real intelligence in our technology that
enables us to detect neural activity, amplify nerve signals,
convert signals to digital form, and geolocate nerves, with
approximately 3000 times greater sensitivity than the closest
available sensing technology in the market today. We look forward
to working closely with the NFR team and leveraging their
expertise.”
The Company’s catheter-based technology is being
developed to do two things: sense neural signals associated with
pain or disease and precisely target those nerves for treatment.
Autonomix believes this technology is a better alternative to the
current approaches commonly used today, where doctors either rely
on systemic drugs like opioids that lose effectiveness and have
unwanted side effects or treat suspected areas blindly in hopes of
hitting the right nerves, an approach that is often inaccurate and
can miss the target and even cause collateral damage to surrounding
parts of the body.
The Company is initially developing its
technology to address pancreatic cancer-related pain. Current
approaches, primarily relying on opioids or invasive ethanol
injections, can provide only limited relief and may lead to risky
side effects. For more information about the Company’s technology,
please visit autonomix.com.
About NoiseFigure Research,
Inc.
NFR is a leader in democratizing
access to application-specific integrated circuit (ASIC)
services in addition to recent offerings into the
manufacturing of PCBs, substrates, and flexible
electronics. Since our inception in 2009, NFR has been
dedicated to empowering developers with world-class custom ASICs
and ASIC services. Our expertise spans Analog, RF/uWave, and
Mixed Signal chip design, including packaging and related
materials. By adding PCB, substrate, and flexible electronics
manufacturing to our portfolio, we further lower the barriers for
innovation. Our products and services cater to a wide range of
industries, including Commercial, Military, Government, and
Aerospace, enabling customers to realize their visions. We are
deeply committed to supporting our customers' endeavors and are
excited to continue driving advancements in technology and
manufacturing.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain, a condition that can cause debilitating
pain and needs an effective solution. However, our technology
constitutes a platform with the potential to address dozens of
indications, including in cardiology, renal denervation and chronic
pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward looking statements in this press release
include, without limitation, the timing of the Company’s planned
pivotal trial. Such forward-looking statements can be identified by
the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’
‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’
‘plans,’ and ‘proposes.’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the offering circular filed
with the U.S. Securities and Exchange Commission (“SEC”) on January
26, 2024. Forward-looking statements speak only as of the date of
the document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024